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Abstract OBJECTIVE: Silver-Russell syndrome is heterogeneous both clinically and geneti-
cally. The best known genetic aberrations existing in this syndrome are an 11p15 
epimutation, present in 20–60% patients, and a maternal uniparental chromosome 
7 disomy (7–15%) (upd(7)mat). Children with SRS suffer from physical growth 
impairments – intrauterine and after birth. MATERIAL AND METHODS: The study 
group consisted of 38 children aged 2 to 17 (x=8.9±4.0 years). These children had 
undergone a genetic analysis in search for the 11p15 epimutation and the upd(7)
mat. Somatic growth was also analysed in terms of birth parameters and postna-
tal BMI, weight and height. The aforementioned parameters were compared in 
a subgroup of children with the genetic aberrations and with a control group of 
children born with IUGR. RESULTS: In the study group a mean weight SD on birth 
was –3.41±1.22, the birth height was –1.25±2.08 SD and a head circumference of 
–3.56±1.93 SD. No significant differences were noted between the SRS study group 
and the control group in reference to weight and head circumference (p>0.05). Such 
difference was, however, seen in birth height. Children with 11p15 epimutation had 
significantly lower weight and height at birth, but a significantly larger head cir-
cumference than children without this genetic aberration. When analysing further 
development of children with SRS, a significantly smaller height SD, body mass 
and BMI was observed, compared with children from the control group. CONCLU-
SIONS: Children with SRS present impaired somatic development compared to 
children with IUGR, and these with a genetic aberration develop worse.
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INTRODUCTION
Silver-Russell Syndrome is a heterogeneous syndrome 
both in the clinical and the genetic aspect (Wollmann et 
al. 1995; Price et al. 1999; Netchine et al. 2007; Bruce et 
al. 2009; Bartholdi et al. 2009; Schönherr et al. 2006). It 
presents a wide spectrum of clinical signs, with a varied 
manifestation of dysmorphic features including: trian-
gular shaped face, prominent frontal eminence, rela-
tive macrocephaly, ear lobe structure disorders, small 
mandible, thin vermilion zone with a long philtrum, 
lip corners pointing downward and body asymmetry 
(Wollmann et al. 1995; Price et al. 1999; Netchine et al. 
2007; Bruce et al. 2009). The best known genetic aber-
rations in this syndrome include the 11p15 epimutation 
(20–60%) and the maternal uniparental disomy of chro-
mosome 7 (7–15%).
Silver-Russell Syndrome is characterised by an intra-
uterine growth retardation with a postnatal height defi-
cit. Neonates with SRS are born on time and their birth 
weight is usually under –2 SD. After birth these children 
present with dwarfism with normal body proportions. 
Growth rate is constant, but low gains in height with-
out catch-up growth constitute to an intensification of 
growth retardation (Wollmann et al. 1995; Price et al. 
1999; Netchine et al. 2007; Bruce et al. 2009; Bartholdi 
et al. 2009; Schönherr et al. 2006).
Height deficit is among the most serious impair-
ments in children with SRS (Toumba et al. 2010). Such 
children do not achieve their genetic growth potential 
and in adult age they are significantly shorter (Cut-
field et al. 2007). In contrast with most children born 
with IUGR, patients with SRS do not present catch-up 
growth (Wollmann et al. 1995; Mascarenhas et al. 2012). 
Their growth rate is very low in postnatal and early 
childhood periods (Cutfield et al. 2007). At the age of 4 
they have a standard deviation of height of –3.5 to –4.4 
(Wollmann et al. 1995; Cutfield et al. 2007; Binder et al. 
2011) and their growth spurt occurs around the age of 
10, constituting to early puberty and a reduction of final 
height (Wakeling, 2011).
Height deficit deteriorates during the whole child-
hood period, leading to a final height of –3.6 to –2.9 
SD (Wollmann et al. 1995; Toumba et al. 2010; Tanner 
et al. 1975; Davies et al. 1988). Tanner et al. (Tanner et 
al. 1975) described a natural growth history of chil-
dren with SRS untreated with growth hormone. They 
described the maximal height of women as 147cm 
and the maximal height of men as 153.5cm. Twenty 
years later, a long-term observation was conducted by 
Wollmann (Wollmann et al. 1995) on a group of 386 
patients. He estimated the mean height of an adult man 
to 151.2cm and of an adult women to 139.9 cm.
STUDY GOAL
The goal of this study was an assessment of somatic 
growth in a selected group of Polish children with SRS. 
MATERIAL AND METHODS:
The study included 38 children at the age of 2 to 17 
years (x=8.9±4.0 years) diagnosed with Silver-Russell 
syndrome based on phenotype features, 18 (47.4%) girls 
and 20 (52.6%) boys therein. To the study qualified were 
children who fulfilled the diagnostic criteria of SRS by 
Wollmann et al. (1995) from 1995 and by Prince et al. 
from 1999.
All the children were under observation/care of 
Department of Pediatrics, Endocrinology, Diabetology, 
Metabolic Diseases and Cardiology of Developmental 
Age, Pomeranian Medical University in Szczecin or 
other centres in Poland (30 children from Szczecin, 3 
from Warsaw and 5 from Cracow).
These children had a DNA analysis in search of 
a maternal uniparental disomy of chromosome 7 
(mUPD7) and a 11p15 epimutaion. These tests were 
done in the Cytogenetics Unit, Department of Pathol-
ogy, Pomeranian Medical University in Szczecin. 
To diagnose mUPD7 the microsatellite polymor-
phism phenomenon was used, that is an analysis of 
selected microsatellite markers from the child and 
from its parents. Confirming mUPD7 was based on 
a family analysis of the existence of a polymorphism 
of six microsatellite markers located in regions criti-
cal for the Silver-Russell syndrome: a region including 
the GRB10 gene on the p arm of chromosome 7 and a 
region including the IGFBP-1 and IGFBP-3 genes on 
the q arm of that chromosome. Six polymorphic STRP 
markers were amplified in a polymerase chain reaction 
(PCR) with specifically 5’-fluorescent marked prim-
ers. The amplification products had undergone elec-
trophoresis on polyacrylamide gel, on 3130 ABI Prism 
(Applied Biosystems, USA) and analysed using the 
Gene Mapper ID-X 1.1 programme. With this method 
the size of given loci and their heterozygosity was deter-
mined in parents and in their child. In 6 (15.8%) cases 
it was not possible to acquire full genetic material, i.e. 
DNA from the parents, inter alia because of lack of 
contact or the death of one of the parents. Therefore 
mUPD7 analysis was done in 32 children. MS-MLPA 
technique (Methylation Specific Multiplex Ligation – 
dependant probe amplification) utilizing a dedicated 
SALSA MLPA, ME030 BWS/RSS kit made by MRC-
Holland b.y. and used according to the manufacturers 
guidelines was used to assess the methylation anomalies 
in the 15.5 region of chromosome 11. A kit includes 26 
probes specific for the 11p15 region. 11 of them gave 
information on possible methylation dysfunctions of 
that region. Results were read and analysed using the 
GeneMarker 1.7 programme. For this test only isolated 
genetic material from the child was needed. Therefore, 
such an analysis was performed in the entire study 
group, that is in 38 children. 
Each child was weighed, measured and had a BMI 
calculated. Based on available medical history, in each 
of the study group child anthropometric parameters 
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(weight, length, head circumference) were assessed at 
birth and in later periods of life. The data from birth 
(weight, length, head circumference) were corrected 
with the length of pregnancy and the child’s gender, 
compared with tables and input on percentile popu-
lation nets of Polish children by I. Palczewska and Z. 
Niedźwiecka from 2001 (Palczewska et al. 2001).
On each visit taking place every 6 months height, 
weight, head circumference and BMI measurements 
were taken. The results were input on percentile popu-
lation nets of Polish children by I. Palczewska and Z. 
Niedźwiecka from 2001 (Palczewska et al. 2001), con-
sidering age and gender. Children born premature were 
classified based on the percentile population nets of 
Polish children by I. Palczewska and Z. Niedźwiecka 
from 1995 (Palczewska et al. 1995) for pre-term chil-
dren (i.e. born before a gestational age of 37 complete 
weeks). Standard deviations (SD) of height, weight and 
head circumference were also calculated. In the study 
group, 12 children were treated with growth hormone 
due to somatotroph pituitary insufficiency or IUGR. 
In the study group, sub-groups of children with and 
without a genetic aberration were created and both 
sub-groups were then compared in terms of somatic 
development.
The control group consisted of 32 children at the age 
of 2 to 17 years (x=9.6±3.9 years) – 17 (53.1%) girls and 
15 (46.9%) boys therein, chosen randomly to match 
age and gender of children from the study group. These 
children were born with intrauterine growth retarda-
tion, that is with a birth weight ≤–2 SD in relation to 
gestational age and gender without dysmorphic fea-
tures. They also presented with afterbirth growth retar-
dation, i.e. height ≤–2 SD for their age and gender. In 
the control group an analysis of somatic development 
was performed, the same as in the study group. The 
control group was a reference point in a comparison of 
the somatic development of the study group. 16 chil-
dren from the control group were treated with growth 
hormone in a standard dose because of somatotroph 
pituitary insufficiency or dwarfism as a result of intra-
uterine growth retardation.
RESULTS
Genetic analysis
Out of 38 examined children, genetic aberrations spe-
cific for SRS were confirmed in 9 (23.7%). Only in one 
(3.1%) child the maternal uniparental disomy of chro-
mosome 7 (mUPD7) was confirmed. In 8 (21.1%) chil-
dren an 11p15 epimutation was confirmed.
Somatic development of children with SRS – birth data
Children from the study group were born between the 
31st and 42nd week of gestation (x=38.56±2.46). Only 
8 (21.1%) of them were born preterm (gestational age 
<37 weeks)
In the control group the length of pregnancy varied 
from 32 to 41 weeks (x=38.56±1.81). As in the study 
group, in case of 8 children (25%), the pregnancy ended 
pre-term.
The status of children from the study group, 
expressed by Apgar Score in the 5th minute after birth 
ranged from 5 to 10 points (x=8.62±1.30). 32 (83.8%) 
children were born in a good condition, i.e. 8–10 points 
in the Apgar Score, while 6 (16.2%) in a fair condition 
with 4–7 points.
In the control group 27 (84.4%) children were born 
in a good condition and 5 (15.6%) in a fair condition.
On Figure 1 compared are the birth data (length, 
weight and head circumference) of children from the 
control and study groups.
The average weight on birth of children from the 
study group was 2 010 g, birth weight SD was –3.41. 
Birth length was 46.89 cm average, –1.25 SD under 
mean values. Average head circumference was 31.59 cm, 
which is –3.56 SD.
Between the study and the control groups no signifi-
cant differences were noted in weight on birth, how-
ever, children from the study group were significantly 
shorter.
The boy diagnosed with maternal uniparental 
disomy of chromosome 7 was born after 39 weeks 
through a caesarean section due to breech presenta-
tion and irregular heart rate. Birth weight was 1 660 g, 
i.e. –4.96 standard deviation; birth length was 43 cm 
(–4.0 SD); head circumference was 31 cm (–4.24 SD). 
The boy scored 3/6/8 points on Apgar score.
Children with the 11p15 epimutation were born 
after 36 to 41 weeks (x=38.8±1.64) and their Apgar 
score at the 5th minute after birth was 6 to 10 points 
(x=8.25±1.16).
Anthropometric parameters of children with the 
11p15 epimutation measured at birth are presented on 
Figures 2–4.
Fig. 1. A comparison of birth length, weight and head 
circumference SD of children from the study and control groups 
(mean values with 95% confidence intervals).
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Children with the 11p15 epimutation had a stan-
dard deviation of birth weight also significantly lower 
(p=0.007) (x=–4.54±1.20) than children without this 
genetic disorder (x=–3.10±1.04).
Unlike the height and weight standard deviations, 
the standard deviation of head circumference of chil-
dren with the 11p15 epimutation was significantly 
larger (p=0.002) (x=−1.65 SD±1.67), compared to chil-
dren without this genetic aberration (x=−4.05±1.69).
As seen on figures 2 and 3, children with the 11p15 
epimutation were significantly smaller and lighter than 
children without this mutation. Moreover, children 
with the 11p15 epimutation had a larger, although not 
significantly, head circumference (Figure 4.).
Children with a genetically confirmed 11p15 epi-
mutation had a significantly (p=0.048) smaller height 
after birth. Birth height SD in these children ranged 
from –6.05 to 0.67 (x=−2.81±2.33). Children without 
the 11p15 epimutation had a birth height SD between 
–5.25 and 2.75 (x=−0.82±1.83).
A significant (p=0.007) difference between the birth 
weight expressed in SD in children with the 11p15 epi-
mutation and children without this genetic aberration 
was shown. Children with the 11p15 epimutation had a 
birth weight SD of –6.03 to –2.88 (x=−4.54±1.20), while 
birth weight SD of children without this genetic aberra-
tion ranged from –4.96 to –1 (x=−3.10±1.04).
Further somatic development
The data regarding age, height, weight and BMI of the 
control and study groups are shown on figure 5. The 
age of children from the study group was between 2 and 
17 years (x=8.91±4.02 years) and in the control group 
between 2 and 18 years (x=9.63±3.93).
A statistically significant height, weight and BMI 
deficit (expressed in SD) was seen in children from the 
study group, compared to the control group.
Table 1 shows a profile of children from the study 
group, based on their genetic aberrations. 9 children 
had a genetically confirmed mutation; 11p15 epimuta-
tion in 8 and a maternal uniparental disomy of chromo-
some 7 in 1 case. 
A significant difference in height SD of children with 
a genetic change was seen, compared to children who 
only had phenotype features of the Silver-Russell Syn-
drome. Mean height expressed in SD of children with a 
genetic change was notably lower.
Children with Silver-Russell Syndrome had a signifi-
cantly (p<0.001) continuously increasing height deficit. 
Mean height deficit SD deteriorated from –1.25 after 
birth to –3.48 at the age of two.
Figure 6 compares the height of children from the 
study and control groups in subsequent years.
Statistically significant lower values of height SD in 
the study group, compared to the control group, were 
also seen in age groups of 5–10 and at the age of 16. 
Predicted final height was also significantly lower in the 
study group than in the control group.
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Fig. 2. Birth length SD of children with 11p15 epimutation.
Fig. 3. Birth weight SD of children with the 11p15 epimutation.
Fig. 4. Head circumference SD of children with the 11p15 
epimutation.
Birth length SD (x=–2.81±2.33) in children with 
the 11p15 epimutation was also significantly lower 
(p=0.048), compared to the children without this 
genetic disorder (x=–0.82±1.83).
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Children with a phenotypically diagnosed SRS had 
a significantly lower weight than in the control group 
(p=0.001).
Standard deviation weight gains were compared in 
the study group at the 12th and 18th month after birth. 
No statistically significant weight deficit deterioration 
was seen in the 12th and 18th month after birth. Body 
mass standard deviation in the study group did not 
differ significantly in that period either. Weight mea-
surements acquired in the control group at 12th and 
18th months after birth were insufficient to conduct 
statistical analysis.
Figure 7 shows a comparison on weight of children 
from the control and study groups in subsequent years.
After birth no significant differences were seen 
between the weight of children from the control and 
study groups.
Body mass expressed in standard deviation in chil-
dren from the study group, compared to the control 
group, was statistically significant at ages from 2 to 10, 
at 16 and at 17.
While analysing the development process of the 
child with maternal uniparental disomy of chromosome 
7, an improvement of both weight and height deficits 
was observed, especially after introducing recombinant 
human growth hormone therapy at the age of 10. The 
boy responded well to growth hormone treatment and 
achieved a height of –2 SD (approximately 3rd percen-
tile) at the age of 12. 
In subsequent years of observation the differences 
in height between the group of children with the 11p15 
epimutation and the group without this change were 
not significant. However, between the age of 11 and 17 
a statistically significant (p=0.003) higher height SD 
Tab. 1. Study group profile based on the existence on mUPD7 or 11p15 epimutation.
Examined 
parameter
Negative genetic analysis result n=29 Positive genetic analysis result n=9
p-valuex
(min.–maks.)
SD Median
x
(min.–max.)
SD Median
Age [years] 9.04
(2.00–17.00)
4.05 8.80 8.43
(2.40–16.20)
4.12 7.75 0.579
Height [cm] 118.61
(78.90–159.70)
22.02 117.10 108.71
(64.60–158.50)
27.61 111.15 0.371
Height [SD] −2.98
(−5.93–−1.17)
1.11 −2.87 −4.81
(−9.71–−1.86)
2.55 −4.21 0.038
Weight [kg] 20.78
(7.70–42.30)
9.56 18.25 16.61
(5.84–36.30)
9.83 14.35 0.267
Weight SD −3.04
(−5.43–−1.35)
1.01 −2.93 −4.02
(−5.97–−1.56)
1.59 −3.95 0.082
BMI 13.95
(11.11–20.43)
2.09 13.13 12.99
(10.29–17.05)
2.13 12.51 0.163
BMI  SD −1.35
(−2.88–0.39)
0.85 −1.38 −1.76
(−3.47–0.40)
1.15 −1.87 0.267
N - group size, x - arithmetic mean; SD - standard deviation; p - statistical significance
Height SD Weight SD BMI SD
study control
Group type 
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Fig. 5. Standard deviation (SD) of height, weight and BMI in 
children from the study and control groups (mean values with 
95% confidence intervals).
Fig. 6. Height SD of children from the study and control groups in 
subsequent years (mean values with 95% confidence intervals).
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was observed in the group of children with 11p15 epi-
mutation compared to children without it.
Figure 8 compares height standard deviation 
between children with the 11p15 epimutation and chil-
dren without this genetic aberration.
The group of children with the 11p15 epimutation 
had a statistically significant smaller weight SD com-
pared to children without this genetic change. From 
birth until the age of 6 this difference was also signifi-
cant (p<0.02) for mean weight SD=–4.64 for children 
with the 11p15 epimutation and –3.35 for children 
without this epimutation. At the age of 6 and 7 a smaller 
deficit of weight expressed in SD was observed in the 
group without the genetic mutation, but this difference 
was not significant statistically. In subsequent years the 
difference in weight SD between both groups did not 
differ significantly.
Figure 9 compares weight SD of children with and 
without the 11p15 epimutation.
DISCUSSION
Until lately the diagnostic of SRS relied exclusively on 
phenotype features. The advancement in many fields of 
medicine, most importantly genetics, allowed introduc-
ing molecular testing to diagnose this condition.
Genetic diagnostic of the Silver Russell Syndrome 
is based mainly on identifying the two main genetic 
changes, namely the maternal uniparental disomy of 
chromosome 7, occurring in 7–10% cases (Binder et al. 
2011; Kotzot et al. 2000; Eggermann et al. 2009; Moore 
et al. 1999; Schönherr et al. 2007; Bernard et al. 1999; 
Kim et al. 2005) and the 11p15 epimutation, seen in 
20–65% children (Netchine et al. 2007; Gicquel et al. 
2005; Bliek et al. 2006; Eggermann et al. 2008).
In the above study the maternal uniparental disomy of 
chromosome 7 was observed in only one child (3.1% of 
children with phenotype SRS features), while the 11p15 
epimutation was confirmed in 8 (21%) children. Egg-
ermann showed a similar incidence of mUPD7 – 2.3% 
(Eggermann et al. 2009), but achieved worse results with 
11p15 epimutation – 14.9% (Eggermann et al. 2008).
In the studied group of children with a phenotype 
diagnosis of SRS, birth weight SD was on average 
–3.42±1.22, similar to the study group of Netchine 
(Netchine et al. 2007) (x=–3.1±1.2 SD) and Binder 
(Binder et al. 2008) (x=–3.12±1.11 SD). Four children 
with a birth weight of over –2 SD and a phenotype 
typical for SRS were also qualified to the study. Price 
(Price et al. 1999) had also included 6 children with 
the typical phenotype for SRS and a birth weight over 
–2 SD to his study. Out of these children, 3 presented 
with body asymmetry and one of them was diagnosed 
with maternal uniparental disomy of chromosome 7. 
These children were born with substantially lower birth 
weight than their siblings and their birth parameters 
were also inadequate to the height and weight of their 
parents (Price et al. 1999). In the study group, the SD 
of height at birth was on average –1.25. This score dif-
fered from data provided by Netchine (Netchine et al. 
2007) and Binder (Binder et al. 2008) (x=–4.1±1.5 and 
x=–3.06±1.52; respectfully). In these two studies, an 
11p15 epimutation was confirmed in two children with 
a birth length of over –2 SD (respectfully +0.33 SD and 
+0.67 SD).
Mean head circumference SD was –3.36. This result 
differs substantially from data provided by Netchine 
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Fig. 7. Weight SD of children from the study and control groups in 
subsequent years (mean values with 95% confidence intervals).
Fig. 8. Height standard deviation of children with the 11p15 
epimutation and children without this genetic aberration in 
subsequent years (mean values).
Fig. 9. Weight SD of children with and without the 11p15 
epimutation in subsequent years (mean values).
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(Netchine et al. 2007) and Binder (Binder et al. 2008) 
(–1.5 SD±1.1 and –0.96 SD±1.29; respectfully). In our 
study, the boy with maternal uniparental disomy of 
chromosome 7 did not present with a relative macro-
cephaly on birth (birth weight SD of –4.96; birth length 
SD of –4.0; head circumference SD on birth of –4.24). 
A head circumference large in relation to body height 
was also not seen in 4 children with 11p15 epimutation, 
moreover, one girl from this group had an opposite 
situation (birth height SD of +0.67; head circumference 
SD of –2.11). Similar results on “relative’ macrocephaly 
after birth in children with phenotype features of SRS 
were also recorded by Eggermann et al. (2009) and 
Wakeling et al. (2010).
The differences in birth parameters of children with 
SRS phenotype features resulted probably from dis-
tinct measurement methodology of height and head 
circumference used in many hospitals. In some cases 
systematic error cannot be excluded. Moreover, a part 
of researches adopted very strict diagnostic criteria for 
low birth height and head circumference (Netchine et 
al. 2007; Binder et al. 2008).
The aforementioned results and literature data prove 
that with age the height deficit deteriorates, especially 
in children with a maternal uniparental disomy of 
chromosome 7 and a relative macrocephaly develops 
(Binder et al. 2008). This disorder in most evident in 
first year after birth. Similar observations were made in 
many other publications (Netchine et al. 2007; Binder 
et al. 2008; Kotzot, 2008). It is commonly known, that 
severe somatic development disorders in children with 
SRS are seen prenatal and after birth the deterioration 
of weight and height growth rate continues.
In a group of 386 patients with SRS phenotype Woll-
mann et al. (1995) conducted an analysis of somatic 
development parameters. He observed that the growth 
of these children can be divided into four distinctive 
phases: intrauterine, neonate-infant and toddler (early 
childhood), childhood and adolescent. Worse intra-
uterine development was, according to this author, a 
result of a progressing placenta insufficiency – small 
size and calcifications of this organ were observed in 
1/3 of mothers. After birth these children presented 
with severe somatic growth retardation, both in weight 
with mean SD of –4.0 and in height. Contrary to other 
parameters, head circumference of these children was 
on the lower border of the normal range. During early 
childhood, up to the age of 3, children with SRS did 
not experience catch-up growth. Height SD was –4.6 on 
average. Between the ages of 3 and 11 the growth curve 
of these children shifted to higher values with a mean 
height SD of –3.9. No pubertal growth spurt occurred. 
The height of an adult man with SRS was approximately 
–3.7 SD, the height of an adult woman –4.2 SD. Weight 
deficit was not as severe as the height deficit. From birth 
to the age of 3, the weight of these children remained 
on a stable level of approximately –4 SD. During child-
hood (age 4–12) weight gains were substantially higher, 
–3 SD averagely. In those studies the height deficit was, 
therefore, larger than the deficit of weight.
Similar results were also observed in this study. 
Moreover, the somatic development was also compared 
between children with a phenotype diagnosis of SRS 
and children with IUGR without dysmorphic features. 
This comparison showed a noticeably smaller weight 
and height of children with SRS.
Children with 11p15 epimutation had a significantly 
smaller height up to the age of 2, compared to children 
without this genetic mutation. In a later period of life, 
children with 11p15 epimutation developed “better” 
and achieved a significantly higher height at 11 to 17 
years. Children with 11p15 epimutation did not, how-
ever, achieve a greater height at the age of 17. Neither 
children with 11p15 epimutation, nor these without this 
genetic mutation achieved expected height at the age 
of 17. The differences between expected and achieved 
height at the age of 17 were statistically significant in 
these groups.
The weight of children with 11p15 epimutation was 
significantly smaller until the age of 5, compared to the 
group of children without this genetic mutation. In fur-
ther years no significant difference between weight was 
observed between these groups. Height deficit is the 
most severe anomaly in children with SRS. Progressing 
during the entire childhood period, it leads to an adult 
height of –3.6 SD (Bliek et al. 2006). 
Tanner et al. (1975) presented a natural history of 
the growth of children with SRS. These studies show 
that final height of these children is approximately 
–2.9 SD. Studies conducted by Wollmann et al. (1995) 
confirmed earlier observations. They include informa-
tion on final height of children with SRS, which turned 
out to be smaller than expected.
CONCLUSIONS
Children with SRS have a considerable somatic develop-
ment impairment with a lack of catch-up growth after 
birth. Therefore, children with SRS were significantly 
shorter compared to children with intrauterine growth 
retardation without dysmorphic features. Moreover, 
children with 11p15 epimutation grew slower than chil-
dren without this genetic change.
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